Valrubicin (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent.
VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Media Articles Related to Valstar (Valrubicin)
Micromedic reports successful clinical study results for monitoring bladder cancer recurrence with the CellDetect non-invasive test
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.02.04]
Micromedic Technologies Ltd., has announced the results of a blinded, multi-center clinical study using the CellDetect non-invasive technology to detect bladder cancer recurrence in patients with a...
New data provide evidence that Hexvix can improve the overall survival in bladder cancer patients
Source: Urology / Nephrology News From Medical News Today [2015.01.30]
Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that a study on the impact of Hexvix on survival in bladder...
Source: MedicineNet Biological Therapy Specialty [2015.01.08]
Title: Bladder Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/8/2015 12:00:00 AM
Bladder Cancer Causes, Symptoms, and Signs
Source: MedicineNet Bladder Cancer Specialty [2014.12.04]
Title: Bladder Cancer Causes, Symptoms, and Signs
Category: Doctor's & Expert's views on Symptoms
Created: 7/11/2005 12:00:00 AM
Last Editorial Review: 12/4/2014 12:00:00 AM
Exercise Linked to Improved Bladder Cancer Survival
Source: MedicineNet Bladder Cancer Specialty [2014.05.22]
Title: Exercise Linked to Improved Bladder Cancer Survival
Category: Health News
Created: 5/21/2014 2:36:00 PM
Last Editorial Review: 5/22/2014 12:00:00 AM
Published Studies Related to Valstar (Valrubicin)
Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. [2011.05]
OBJECTIVE: Patients with bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder are candidates for intravesical (IVe) valrubicin. This post-hoc analysis of data from the pivotal phase 3, prospective, open-label study of valrubicin evaluated the effects of patient characteristics and past treatments on the response to valrubicin... CONCLUSIONS: In these patients with BCG-refractory CIS, complete responders to valrubicin did not differ significantly from partial or nonresponders in the number of prior courses or instillations. The results suggest that therapy with valrubicin may be considered in appropriate candidates who have not responded to prior therapies. Cystectomy should be reconsidered when valrubicin treatment fails.
Topical application of valrubicin has a beneficial effect on developing skin tumors. [2010.08]
Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact...
Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. [2010.02]
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent therapeutic potential with minimal toxicity.
Clinical Trials Related to Valstar (Valrubicin)
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Recruiting]
The purpose of this study is to learn more about how well the drug valrubicin (VALSTARŪ)
works to help treat the patient's cancer when administered through a nephrostomy tube
inserted through their back into their kidney. The study is also being done to determine how
safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in
which the drug is eliminated from the human body (Pharmacokinetics or PK).
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Not yet recruiting]
The use of a designed viral vector that can destroy cancer cells while leaving normal cells
largely unharmed. The virus also stimulates an immunological response by producing a special
factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It
forms the hypothesis that this regimen may be used for people who have failed current forms
of treatment and are recommended for cystectomy. It is with hope that this novel therapy
will be able to delay or potentially avoid cystectomy for this patient population. Bladder
instillation of this agent causes little long lasting side effects and may drastically
improve the stimulation of the immune system for local cancer cell death as well as
destroying those tumor cells that may have travelled to regional lymph nodes or distant